Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Oct;39(5):1045-1052.
doi: 10.1007/s10557-024-07594-w. Epub 2024 Jun 12.

Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial

Nkanyiso Hadebe et al. Cardiovasc Drugs Ther. 2025 Oct.

Abstract

Purpose: Coronary artery bypass grafting (CABG) on cardiopulmonary bypass (CPB) is associated with myocardial ischemia-reperfusion injury (IRI), which may limit the benefit of the surgery. Both experimental and clinical studies suggest that Intralipid, a lipid emulsion commonly used for parenteral nutrition, can limit myocardial IRI. We therefore aimed to investigate whether Intralipid administered at reperfusion can reduce myocardial IRI in patients undergoing CABG on CPB.

Methods: We conducted a randomized, double-blind, pilot trial in which 29 adult patients scheduled for CABG were randomly assigned (on a 1:1 basis) to receive either 1.5 ml/kg Intralipid 20% or Ringer's Lactate 3 min before aortic cross unclamping. The primary endpoint was the 72-h area under the curve (AUC) for troponin I.

Results: Of the 29 patients randomized, 26 were included in the study (two withdrew consent and one was excluded before surgery). The 72-h AUC for troponin I did not significantly differ between the control and Intralipid group (546437 ± 205518 versus 487561 ± 115724 arbitrary units, respectively; P = 0.804). Other outcomes (including 72-h AUC for CK-MB, C-reactive protein, need for defibrillation, time to extubation, length of ICU and hospital stay, and serious adverse events) were similar between the two groups.

Conclusion: In patients undergoing CABG on CPB, Intralipid did not limit myocardial IRI compared to placebo.

Trial registration: ClinicalTrials.gov Identifier: NCT02807727 (registration date: 16 June 2016).

Keywords: Cardioprotection; Coronary artery bypass grafting; Intralipid; Ischemia–reperfusion injury.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: The trial was authorized by the Human Research Ethics Council (HREC) of the University of Cape Town (number: 806/2014) and by the Medicines Control Council (MCC) of South Africa (number: 20150807). The trial was registered in ClinicalTrials.gov before the start of the study (registration number: NCT02807727) on June 16, 2016. Consent to Participate: The trial was conducted according to the requirements of the Declaration of Helsinki. Written informed consent was obtained from all individual participants included in the study. Consent for Publication: N/A. Competing Interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Experimental protocol of the study. MLR: Modified Lactate’s Ringer; ICU: intensive care unit
Fig. 2
Fig. 2
Flow chart of the study. LEVF: Left ventricle ejection fraction
Fig. 3
Fig. 3
Assessment of myocardial injury (cardiac troponin I). Geometric means and 95% confidence intervals of cardiac troponin I levels in blood are presented for the Control group (orange circles) and the Intralipid group (blue squares) at baseline and 1, 6, 9, 12, 24, 48, and 72 h after unclamping the aorta
Fig. 4
Fig. 4
Assessment of myocardial injury (CK-MB). Geometric means and 95% confidence intervals of CK-MB levels in blood are presented for the Control group (orange circles) and the Intralipid group (blue squares) at baseline and 1, 6, 9, 12, 24, 48, and 72 h after unclamping the aorta

References

    1. Khan MA, Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12:e9349. 10.7759/cureus.9349. - PMC - PubMed
    1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–35. 10.1056/NEJMra071667. - PubMed
    1. Calder PC, Waitzberg DL, Klek S, Martindale RG. Lipids in parenteral nutrition: biological aspects. JPEN J Parenter Enteral Nutr. 2020;44(Suppl1):21–7. 10.1002/jpen.1756. - PubMed
    1. Rahman S, Li J, Bopassa JC, Umar S, Iorga A, Partownavid P, Eghbali M. Phosphorylation of GSK-3β mediates intralipid-induced cardioprotection against ischemia/reperfusion injury. Anesthesiology. 2011;115:242–53. 10.1097/ALN.0b013e318223b8b9. - PMC - PubMed
    1. Li J, Iorga A, Sharma S, Youn JY, et al. Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology. 2012;117:836–46. 10.1097/ALN.0b013e3182655e73. - PMC - PubMed

Publication types

MeSH terms

Associated data